By Steve Usdin
Contributing Editor

WASHINGTON - The legal battle over worldwide markets for stem cell selection technology, pitting CellPro Inc. against the licensees of Johns Hopkins' CD34+ technology, are taking place in the context of a profound scientific uncertainty: both the companies and leading researchers acknowledge that the overall efficacy of blood stem cell transplantation is unknown.